AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 38753452
Drug: Early initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Early initiation of direct oral anticoagulants
Trial: 38753813
Drug: Dihydroartemisinin-piperaquine (DP)
RxNorm normalized name: .alpha.-dihydroartemisinin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroartemisinin-piperaquine (DP) + single-dose azithromycin (AZ)
Trial: 38754056
Drug: Niraparib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niraparib (200 or 300 mg once daily), Dostarlimab (500 mg once every 3 weeks for four 21-day cycles, followed by 1,000 mg once every 6 weeks), Bevacizumab (15 mg/kg once every 3 weeks)
Trial: 38754068
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy (dolutegravir plus emtricitabine)
Trial: 38754101
Drug: Web-based psychological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based psychological intervention incorporating cognitive behavioral therapy tools, diabetes self-care promotion, and mindfulness
Trial: 38754593
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of electrospun poly (L-lactide-co-caprolactone) and formulated porcine fibrinogen (PLCL/Fg) dressing
Trial: 38754780
Drug: Neoadjuvant dabrafenib
RxNorm normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Neoadjuvant dabrafenib 150 mg (orally twice per day) plus trametinib 2 mg (orally once per day) for 52 weeks
Trial: 38754876
Drug: Prognostic factors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prognostic factors assessed at 1-month post-surgery for subjective UL function (QuickDASH) at 6 months post-cancer treatment.
Trial: 38754877
Drug: Living With
RxNorm normalized name: Typhoid Vaccine Live
DrugBank: Typhoid Vaccine Live (DB11050)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Living With the Sun (LWS) + Mission Soleil Réunion's sun protection awareness programme + distribution of hats, sunglasses, and sun creams
Trial: 38754888
Drug: GFAP and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GFAP and UCH-L1 biomarkers used separately and in combination
Trial: 38754991
Drug: Unilateral anterior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unilateral anterior quadratus lumborum block with 30 mL ropivacaine 0.75%
Trial: 38755096
Drug: Atezolizumab 1200
RxNorm normalized name: atezolizumab 1200 MG in 20 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab 1200 mg every 21 days with investigator-selected chemotherapy (carboplatin plus gemcitabine or capecitabine monotherapy) until disease progression or unacceptable toxicity.
Trial: 38755096
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with investigator-selected chemotherapy (carboplatin plus gemcitabine or capecitabine monotherapy) until disease progression or unacceptable toxicity.
Trial: 38755096
Drug: Atezolizumab 1200
RxNorm normalized name: atezolizumab 1200 MG in 20 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab 1200 mg every 21 days with investigator-selected chemotherapy.
Trial: 38755096
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with investigator-selected chemotherapy.
Trial: 38755096
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment arms (Atezolizumab and Placebo) with investigator-selected chemotherapy.
Trial: 38755201
Drug: Bifidobacterium +
RxNorm normalized name: BIFIDOBACTERIUM
DrugBank: Bifidobacterium spp. (DB18530)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifidobacterium + inulin treatment in vitro
Trial: 38755568
Drug: Erenumab, 140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erenumab, 140 mg every four weeks for 16 weeks (post-treatment)
Trial: 38755709
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of apixaban twice a day for the first 3 months and 100 mg of acetylsalicylic acid thereafter
Trial: 38755709
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of acetylsalicylic acid once a day, indefinitely
Trial: 38757982
Drug: Fosmanogepix (FMGX)
RxNorm normalized name: Fosmanogepix
DrugBank: Fosmanogepix (DB15183)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosmanogepix (FMGX) with strong CYP3A4 inhibitor itraconazole
Trial: 38758583
Drug: Weekly text-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly text-based monitoring of 8 PROs plus continuous step count monitoring via Fitbit
Trial: 38758815
Drug: GZ17-6.02 at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GZ17-6.02 at 375 mg PO BID
Trial: 38758815
Drug: GZ17-6.02 in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GZ17-6.02 in combination with doxorubicin or ERBB family inhibitors
Trial: 38758967
Drug: MR-guided focussed
RxNorm normalized name: verapamil hydrochloride Extended Release Oral Tablet [Ethimil MR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MR-guided focussed ultrasound-stimulated microbubble (MRgFUS-MB) treatment
Trial: 38759581
Drug: Propafenone or
RxNorm normalized name: propafenone Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propafenone or Amiodarone infusion
Trial: 38759667
Drug: Adapted EXTREME
RxNorm normalized name: ADAPT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adapted EXTREME regimen (six cycles of fluorouracil 4000 mg/m²)
Trial: 38759886
Drug: Daily egg
RxNorm normalized name: EGG
DrugBank: Egg (DB10529)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily egg consumption for 6 months
Trial: 38760098
Drug: Inebilizumab (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inebilizumab (300 mg) administered intravenously on days 1 and 15 during the randomised period and continued every 6 months for a minimum of 2 years in the open-label period.
Trial: 38760098
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered on days 1 and 15 during the randomised period.
Trial: 38760589
Drug: p75 neurotrophin
RxNorm normalized name: neurotrophin 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: p75 neurotrophin receptor modulation
Trial: 38760800
Drug: Remote family
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remote family education and support program (four, 150 min weekly group sessions) for parents plus treatment-as-usual for patients
Trial: 38760800
Drug: Waiting for
RxNorm normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waiting for the control condition (parents will wait to start the program for 8 weeks) plus treatment-as-usual for patients
Trial: 38760804
Drug: i.v. citicoline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. citicoline (0.5 mg/kg, 2.5 mg/kg, or 5 mg/kg every 12 hours for 5 days)
Trial: 38761068
Drug: Clopidogrel-based dual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel-based dual antiplatelet therapy
Trial: 38761558
Drug: Acceptance-enhanced behavior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance-enhanced behavior therapy (AEBT)
Trial: 38761558
Drug: Pre-treatment TTM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment TTM severity
Trial: 38761811
Drug: Decompressive craniectomy
RxNorm normalized name: TUBE DECOMPRESSION BARD #000395
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decompressive craniectomy plus best medical treatment
Trial: 38761816
Drug: 25 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 μg SpFN/ALFQ
Trial: 38761816
Drug: 50 μg
RxNorm normalized name: penicillin G 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 μg SpFN/ALFQ
Trial: 38761816
Drug: SpFN/ALFQ (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SpFN/ALFQ (both doses)
Trial: 38762187
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein (50 g/day, 2 × 25g)
Trial: 38762187
Drug: Pea protein
RxNorm normalized name: Pea Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pea protein (50 g/day, 2 × 25g)
Trial: 38762187
Drug: Collagen protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collagen protein (50 g/day, 2 × 25g)
Trial: 38762348
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg every 3 weeks plus 5-fluorouracil, leucovorin, oxaliplatin (cohort B)
Trial: 38762348
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg every 3 weeks plus 5-fluorouracil, leucovorin, irinotecan (cohort D)
Trial: 38762522
Drug: Bivalent BA.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalent BA.1 and BA.5 vaccines
Trial: 38762578
Drug: AKI (Acute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AKI (Acute Kidney Injury) without CKRT (Continuous Kidney Replacement Therapy)
Trial: 38762578
Drug: AKI (Acute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AKI (Acute Kidney Injury) with CKRT (Continuous Kidney Replacement Therapy)
Trial: 38762720
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (duloxetine + web-based self-guided CBT) without phone-based MI
Trial: 38762734
Drug: BMC treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMC treatment (autologous bone marrow concentrate and platelet products)
Trial: 38762797
Drug: Pamrevlumab (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamrevlumab (30 mg/kg administered intravenously every 3 weeks; n=181)
Trial: 38762798
Drug: Acetaminophen (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (1 g intravenously every 6 hours for 5 days)
Trial: 38763104
Drug: Capmatinib 400
RxNorm normalized name: CAPMATINIB
DrugBank: Capmatinib (DB11791)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capmatinib 400 mg orally twice daily plus nivolumab 3 mg/kg intravenously every 2 weeks (high-MET group)
Trial: 38763104
Drug: Capmatinib 400
RxNorm normalized name: CAPMATINIB
DrugBank: Capmatinib (DB11791)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capmatinib 400 mg orally twice daily plus nivolumab 3 mg/kg intravenously every 2 weeks (low-MET group)
Trial: 38763257
Drug: COMT major
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COMT major allele carriers (C, G)
Trial: 38763303
Drug: RLRL therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RLRL therapy combined with orthokeratology (RCO)
Trial: 38764430
Drug: Metronomic capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Metronomic capecitabine (500 mg/m2)
Trial: 38764606
Drug: Rimegepant 75
RxNorm normalized name: rimegepant 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rimegepant 75 mg (PRN)
Trial: 38764606
Drug: Rimegepant 75
RxNorm normalized name: rimegepant 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rimegepant 75 mg (EOD+PRN)
Trial: 38764606
Drug: Rimegepant 75
RxNorm normalized name: rimegepant 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rimegepant 75 mg (overall treatment)
Trial: 38764682
Drug: JAB-2485, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JAB-2485, a small-molecule inhibitor of AURKA
Trial: 38765202
Drug: 75.0 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75.0 Gy in 30 fractions with concurrent bevacizumab (BEV)
Trial: 38765202
Drug: Standard plans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard plans (not specified dosage)
Trial: 38765567
Drug: Sparsentan 800
RxNorm normalized name: SPARSENTAN
DrugBank: Sparsentan (DB12548)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sparsentan 800 mg once daily
Trial: 38765784
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (previously received)
Trial: 38766125
Drug: Xanthine oxidase
RxNorm normalized name: Xanthine oxidase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xanthine oxidase inhibitors (XOIs) for urate-lowering treatment (ULT)
Trial: 39426967
Drug: Xanthine oxidase
RxNorm normalized name: Xanthine oxidase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xanthine oxidase inhibitors (XOIs)
Trial: 38766125
Drug: Febuxostat (a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Febuxostat (a type of xanthine oxidase inhibitor)
Trial: 38766126
Drug: eIF4A inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: eIF4A inhibitor zotatifin
Trial: 38766126
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with eIF4A inhibitor zotatifin and fulvestrant
Trial: 38767222
Drug: Nonoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonoperative treatment with closed reduction and below-elbow casting
Trial: 38767445
Drug: IN.PACT DCB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IN.PACT DCB (Medtronic) treatment
Trial: 38767513
Drug: Neurocognitive training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurocognitive training (NT) administered weekly for 10 consecutive weeks, supplemented by a structured home exercise programme for 6 days a week over the same 10-week period.
Trial: 38767614
Drug: Dupilumab (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab (300 mg subcutaneous every 2 weeks)
Trial: 38768231
Drug: Gardasil-9 (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gardasil-9 (3 doses administered intramuscularly at 0, 2, and 6 months)
Trial: 38768428
Drug: HBI0101 (BCMA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBI0101 (BCMA CART) therapy, 800 × 10^6 CART cells
Trial: 38768428
Drug: HBI0101 (BCMA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBI0101 (BCMA CART) therapy
Trial: 38768626
Drug: Intravenous tenecteplase
RxNorm normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous tenecteplase (0.25 mg/kg)
Trial: 38769284
Drug: Paliperidone palmitate
RxNorm normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paliperidone palmitate 6-month (PP6M) injection
Trial: 38769284
Drug: Paliperidone palmitate
RxNorm normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paliperidone palmitate 3-month (PP3M) injection
Trial: 38769330
Drug: Ciprofloxacin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (500 mg q 12 hourly) plus Metronidazole (800 mg q 8 hourly) for 2 weeks
Trial: 38769330
Drug: Cefixime (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefixime (200 mg q 12 hourly) plus Metronidazole (800 mg q 8 hourly) for 2 weeks
Trial: 38769543
Drug: Modified TIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified TIL therapy regimen (low-dose cyclophosphamide lymphodepletion followed by TIL infusion without intravenous IL-2)
Trial: 38769543
Drug: Modified TIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified TIL therapy regimen
Trial: 38769624
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no guidance for therapies)
Trial: 38769974
Drug: SARS-CoV-2 mRNA
RxNorm normalized name: SARS-CoV-2 mRNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SARS-CoV-2 mRNA vaccine booster dose (third vaccine dose)
Trial: 38770592
Drug: Deucravacitinib at
RxNorm normalized name: Deucravacitinib
DrugBank: Deucravacitinib (DB16650)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deucravacitinib at 6 mg QD
Trial: 38770592
Drug: Deucravacitinib at
RxNorm normalized name: Deucravacitinib
DrugBank: Deucravacitinib (DB16650)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deucravacitinib at 12 mg QD
Trial: 38770686
Drug: Daily Cannabidiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily Cannabidiol Administration
Trial: 38771152
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg of curcuminoids in turmeric extract capsules and acupressure (group 1)
Trial: 38771622
Drug: Improving Pediatric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Improving Pediatric Obesity Practice Using Prompts (integrated package comprising CDS for obesity treatment)
Trial: 38771808
Drug: Aortic Valve
RxNorm normalized name: VALVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aortic Valve Improved Treatment Approaches (AVITA), an interactive, online decision aid
Trial: 38771808
Drug: Aortic Valve
RxNorm normalized name: VALVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aortic Valve Improved Treatment Approaches (AVITA)
Trial: 38771973
Drug: Distinct types
RxNorm normalized name: collagen type I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Distinct types of therapy activity preferences
Trial: 38771973
Drug: No specific
RxNorm normalized name: Oregano specific IgE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No specific therapy activity or preference
Trial: 38771995
Drug: Ribociclib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribociclib plus endocrine therapy (ET) (600 mg once daily; 3 weeks on, 1 week off)
Trial: 38771995
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy (CT) (docetaxel plus capecitabine, paclitaxel plus gemcitabine, or capecitabine plus vinorelbine)
Trial: 38772477
Drug: Ablative stereotactic
RxNorm normalized name: ABL
DrugBank: Lauric acid (DB03017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ablative stereotactic body radiation therapy (SBRT) delivered using a risk adaptive approach (50 Gy/5 fractions, 60 Gy/8 fractions, 70 Gy/10 fractions)
Trial: 38772477
Drug: Ablative stereotactic
RxNorm normalized name: ABL
DrugBank: Lauric acid (DB03017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ablative stereotactic body radiation therapy (SBRT)
Trial: 38772883
Drug: 240 mg
RxNorm normalized name: aspirin 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mg Dimethyl fumarate (DMF) orally every day for 6 months
Trial: 38772883
Drug: 240 mg
RxNorm normalized name: aspirin 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mg Dimethyl fumarate (DMF)
Trial: 38772898
Drug: ACT intervention
RxNorm normalized name: ACT-101
DrugBank: ACT-101 (DB17000)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACT intervention (Advance Consultations Concerning your Life and Treatment)
Trial: 38773199
Drug: Glycine 0.5
RxNorm normalized name: GLYCINE 0.5 g in 100 g DENTAL PASTE, DENTIFRICE [CAREDO Treating Gingivitis Toothpastes 100g]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycine 0.5 g/kg/day by enteral route
Trial: 38773457
Drug: Preoperative concurrent
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative concurrent chemoradiotherapy (preCRT) with raltitrexed (3 mg/m2 on days 1 and 22) and radiotherapy (50 Gy)
Trial: 38773457
Drug: Preoperative concurrent
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative concurrent chemoradiotherapy (preCRT)
Trial: 38773528
Drug: Primaquine (PQ)
DrugBank: Primaquine (DB01087)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Primaquine (PQ) 0.4-0.5 mg/kg
Trial: 38773543
Drug: Very low-energy
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very low-energy diets (VLEDs); specific dosage and duration not mentioned.
Trial: 38773643
Drug: Stereotactic radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stereotactic radiotherapy (SRT) treatment (24 Gy, single fraction)
Trial: 38773643
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (continuation of anti-seizure medication and neuromodulation)
Trial: 38773653
Drug: Intravenous 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 2% lidocaine bolus of 1.5 mg/kg with induction of anesthesia, followed by a 2.0 mg/kg/h infusion until the end of surgery
Trial: 38773653
Drug: Placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution (normal saline) at the same volume
Trial: 38773653
Drug: Intravenous 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 2% lidocaine
Trial: 38773662
Drug: Telemedicine home-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telemedicine home-based management program including support from a nursing case manager, daily physical activity stimulation, teleconsultations, telemonitoring, and an app for monitoring clinical parameters.
Trial: 38774010
Drug: Tafamidis (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tafamidis (20 mg and 80 mg pooled)
Trial: 38774037
Drug: Extended-release once-nightly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release once-nightly sodium oxybate (ON-SXB)
Trial: 38774425
Drug: Direct factor
RxNorm normalized name: Direct factor Xa inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct factor Xa inhibitors (apixaban, edoxaban, rivaroxaban)
Trial: 38774484
Drug: Intranasal remimazolam
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intranasal remimazolam 1.5mg/kg
Trial: 38774675
Drug: BCG-Denmark (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG-Denmark (single 0.1 ml intradermal injection)
Trial: 38774780
Drug: Behavioral Activation
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral Activation (BA) therapy for 9 weeks